Vertex二季度收入增长12%、上调全年收入指引并详述100亿美元收购Crinetics

Trump insists Iran talks ongoing, says Hormuz could open ’literally by tomorrow’
Introduction & Market Context
Vertex Pharmaceuticals (NASDAQ:VRTX) unveiled its second quarter 2026 financial results on August 3, revealing strong performance across its commercial portfolio and announcing a transformative $10 billion acquisition that will establish rare endocrine diseases as the company’s fifth disease area pillar. The presentation detailed total revenue of $3.33 billion, representing 12% year-over-year growth, while the company raised its full-year 2026 revenue guidance to $13.1-$13.2 billion.
The quarter demonstrated Vertex’s evolution from a cystic fibrosis-focused company into a diversified specialty pharmaceutical organization, with non-CF products CASGEVY and JOURNAVX contributing $126 million in combined revenue and positioned to reach the company’s $500 million-plus non-CF revenue target for 2026. Despite beating analyst estimates on both revenue and earnings, shares declined 1.34% in regular trading to $470.72 and slipped another 0.33% after hours to $469.19, suggesting investors had already priced in solid execution.
Strategic Expansion Through Crinetics Acquisition
The centerpiece of Vertex’s presentation was the announced acquisition of Crinetics Pharmaceuticals for approximately $10 billion, or $8.8 billion net of cash, marking a strategic expansion into rare endocrine diseases. The deal, unanimously approved by both boards of directors on July 6, 2026, is expected to close in the third quarter subject to customary closing conditions.
As illustrated in the company’s updated portfolio structure, the acquisition establishes endocrine diseases as Vertex’s fifth therapeutic pillar alongside cystic fibrosis, hematology, pain, and renal diseases.
The Crinetics deal brings two key assets: PALSONIFY, the first and only once-daily oral therapy for adults with acromegaly that launched in the U.S. in October 2025 with strong early uptake, and atumelnant, a once-daily oral ACTH receptor antagonist in Phase 3 development for congenital adrenal hyperplasia and Phase 2 for ACTH-dependent Cushing’s syndrome. Together, these assets represent a combined peak sales opportunity exceeding $5 billion, according to the presentation.
The company emphasized that Vertex’s commercial and development capabilities are expected to accelerate launches and pipeline development for these endocrine programs, while the acquisition is anticipated to enhance Vertex’s long-term revenue growth trajectory and earnings profile.
Quarterly Performance Highlights
Vertex reported robust second quarter results across multiple dimensions, as summarized in the presentation’s performance overview.
Total revenue of $3.33 billion reflected 12% year-over-year growth, driven by strength across all products and regions. The company achieved non-GAAP operating income of $1.42 billion with a 43% operating margin, while non-GAAP net income reached $1.21 billion, or $4.73 per diluted share. The company maintained a strong balance sheet with $13.6 billion in cash, cash equivalents, and marketable securities at quarter-end.
The detailed financial breakdown shows the composition of Vertex’s revenue streams and profitability metrics.
Combined non-GAAP R&D, acquired IPR&D, and SG&A expenses totaled $1.43 billion in the quarter, reflecting continued investment in multiple mid- and late-stage clinical development programs and expanding commercialization capabilities. The company noted it expects to be at the high end of its full-year expense guidance range of $5.65-$5.75 billion on a non-GAAP basis.
Cystic Fibrosis Leadership and Growth
Vertex’s cystic fibrosis franchise continued to demonstrate strong performance, with global CF revenue reaching $3.21 billion in the second quarter, up 11% year-over-year. The company highlighted that ALYFTREK and TRIKAFTA now reach approximately 95% of all people with CF following recent label expansions.
The presentation detailed ALYFTREK’s progress as the next-generation CF modulator.
ALYFTREK achieved a significant milestone with $1 billion in revenue during the first half of 2026, demonstrating rapid adoption. The drug offers the best CFTR protein function as measured by sweat chloride, combined with once-daily dosing. New data presented at the European Cystic Fibrosis Society meeting showed ALYFTREK is the first medicine to enable nearly two-thirds of younger patients to achieve sweat chloride levels below 30 mmol/L, which represents the median among CF carriers.
The company’s commercial progress in CF was particularly strong internationally, with more than one in three eligible CF patients in the UK and Germany now on ALYFTREK. Vertex secured four new reimbursements in the second quarter (Bosnia, Spain, Austria, and Finland), bringing the total to 25 countries with ALYFTREK reimbursement.
Global regulatory submissions are in progress for ALYFTREK in patients aged 2-5 years and TRIKAFTA in patients aged 1-2 years, which would further expand the eligible patient population. The company is also advancing its next-generation 3.0 family of compounds, with VX-828 having completed dosing and results expected in the second half of 2026.
Non-CF Portfolio Momentum
Vertex made substantial progress in building its non-CF business, with CASGEVY and JOURNAVX demonstrating strong growth trajectories that position the company to achieve its goal of $500 million or more in non-CF product revenue for 2026.
CASGEVY, the company’s gene therapy for sickle cell disease and transfusion-dependent beta thalassemia, generated $76 million in second quarter revenue. The presentation highlighted the therapy’s acceleration toward multi-billion dollar potential.
Key developments for CASGEVY included U.S. approval for patients aged 2 to less than 12 years, regulatory submissions completed in the Kingdom of Saudi Arabia and the U.K. for ages 5 to less than 12 years, and a historic access agreement reached in Germany for SCD and TDT patients aged 12 years and older. The company noted strong trends in Germany following this agreement.
JOURNAVX, Vertex’s non-opioid pain medicine for acute pain, contributed $50 million in second quarter revenue and is on track to deliver greater than 3x prescription growth and greater than 3x revenue growth in 2026 versus 2025. The presentation detailed the launch’s progress across multiple dimensions.
The company added approximately 18,000 new prescribers in the second quarter, bringing coverage to approximately 260 million lives representing over 80% of total covered lives, with approximately 180 million lives having unrestricted access. JOURNAVX established access pathways in approximately 1,400 hospitals and approximately 130 health systems, while the company expanded its field force to approximately 300 personnel to support continued growth.
Pipeline Advancement and Clinical Milestones
Vertex’s presentation showcased significant progress across its broad and deep pipeline, with multiple programs advancing through clinical development and several key milestones achieved or anticipated in 2026.
The company’s comprehensive R&D portfolio spans early research through approved products across five disease areas.
In the renal disease area, povetacicept represents a major near-term opportunity. The company announced that the Biologics License Application for povetacicept in IgA nephropathy has been accepted by the FDA with a PDUFA date of November 30, 2026. The presentation highlighted povetacicept’s potential as a best-in-class treatment based on Phase 3 interim analysis data from the RAINIER study.
Povetacicept was specifically engineered to achieve improved binding affinity for BAFF and APRIL, enhanced potency, favorable pharmacokinetics, and optimized tissue distribution including the kidney. The RAINIER interim analysis data demonstrated reductions in proteinuria, hematuria, and galactose-deficient IgA1, with high rates of background supportive care. The drug features patient-centric attributes including monthly dosing, small volume injection (0.46mL), 27-gauge needle, less than 1.5 second injection time, and at-home administration via subcutaneous autoinjector.
Beyond IgAN, povetacicept demonstrates pipeline-in-a-product potential across multiple B cell-driven diseases.
The OLYMPUS Phase 2/3 pivotal trial in primary membranous nephropathy is underway after completing the Phase 2b portion and selecting the 80mg subcutaneous monthly dose. In generalized myasthenia gravis, a Phase 2 study of 30 patients versus placebo is well underway with enrollment expected to complete by year-end 2026. These indications represent substantial patient populations, with IgAN affecting an estimated 330,000 patients in the U.S. and Europe, pMN affecting approximately 150,000, and gMG affecting approximately 175,000.
In APOL1-mediated kidney disease, inaxaplin is advancing through pivotal development with the AMPLITUDE Phase 3 study on track to complete enrollment by year-end 2026 and interim analysis data expected in early 2027.
The AMPLITUDE study targets approximately 150,000 patients with two APOL1 variants, heavy proteinuria, and no other renal-related comorbidities. If the interim analysis is positive, Vertex plans to file for potential accelerated approval in the U.S. The complementary AMPLIFIED Phase 2 proof-of-concept study is evaluating inaxaplin in an additional approximately 100,000 patients with AMKD and modest proteinuria or AMKD with moderate/severe proteinuria plus diabetes, with results expected in the second half of 2026.
In Type 1 diabetes, Vertex announced significant progress with both its existing zimislecel program and the newly cleared VX-017 universal donor program.
The FDA cleared an IND for VX-017, a blood type O version with a similar target product profile to zimislecel, enabling Vertex to initiate a Phase 1/2 trial in the near term. This development is expected to double the market opportunity from approximately 60,000 to approximately 120,000 patients. The zimislecel Phase 1/2/3 study has resumed dosing patients, with updated program plans expected later in 2026.
Commercial Launch Preparations
With multiple potential product launches on the horizon, Vertex detailed its commercial preparations, particularly for the anticipated povetacicept launch in IgAN following the November 30 PDUFA date.
The company outlined its comprehensive launch strategy across providers, payers, and patients.
Vertex has completed hiring its renal field force, with 90% having nephrology experience, creating what the company describes as the largest field force among APRIL or APRIL/BAFF therapies for IgAN. The company noted that approximately 4,000 nephrologists treat approximately 80% of U.S. IgAN patients. For payer access, Vertex highlighted that approximately 70% of IgAN patients have commercial coverage, with payers recognizing the high value of disease-modifying therapies. The company is establishing patient programs deemed critical for chronic therapies, especially biologics, aiming to enable speed to therapy and personalized support while leveraging best practices from its CF business.
Forward-Looking Statements and Guidance
Vertex raised its full-year 2026 revenue guidance based on strong first-half performance and continued momentum across the business.
The company now expects total revenue of $13.1-$13.2 billion for full-year 2026, up from previous guidance of $12.95-$13.1 billion. This guidance includes expectations for continued growth in CF as well as $500 million or more in revenue from non-CF products. Combined GAAP R&D, acquired IPR&D, and SG&A expenses guidance remained unchanged at $6.3-$6.45 billion, though the company expects to be at the high end of this range. The non-GAAP effective tax rate guidance also remained unchanged at 19.5%-20.5%.
The presentation outlined numerous anticipated milestones across the portfolio.
Key upcoming events include VX-828 results in the second half of 2026, completion of enrollment for suzetrigine Phase 3 studies in diabetic peripheral neuropathy by year-end, VX-670 proof-of-concept results in DM1 in the second half of 2026, inaxaplin AMPLITUDE Phase 3 interim analysis in early 2027, and the regulatory decision on povetacicept for IgAN on November 30, 2026. The company also expects to close the Crinetics acquisition in the third quarter, subject to customary closing conditions.
In cystic fibrosis, Vertex aims to expand the number of people treated through ultra-rare mutations, younger patients, and additional geographies, while driving ALYFTREK adoption in the U.S. and ongoing launches outside the U.S. in patients six years and older. For CASGEVY, the focus is reaching more eligible patients aged 2 and older through the global authorized treatment center network while advancing preclinical assets for gentler conditioning to broaden the eligible patient population.
The company’s strategic vision positions it for sustained long-term growth across five disease area pillars, supported by what management described as a broad, deep, and rapidly advancing R&D portfolio. With the pending Crinetics acquisition adding established and late-stage endocrine assets, multiple pivotal programs advancing, and strong commercial execution across both CF and non-CF products, Vertex’s second quarter 2026 presentation outlined a company in transformation from single-franchise specialist to diversified rare disease leader.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.